Latest NIH funding of IBS Research Stories
LOS ANGELES, July 8, 2014 /PRNewswire/ -- Mark Pimentel, M.D., FRCP(C), FACG, Director, GI Motility Program, Professor of Medicine at Cedars-Sinai Medical Center (Cedars-Sinai), announced today
G-Tech has obtained IRB approval to launch a clinical research study designed to record abnormal myoelectrical activity in subjects with irritable bowel syndrome (IBS). Palo
A patient's viewpoint of the severity of irritable bowel syndrome (IBS) symptoms can be influenced not only by physical symptoms of IBS but broader psychological problems.
LOS ANGELES, June 30, 2011 /PRNewswire/ -- For years, physicians have thought of chronic abdominal pain, also known as irritable bowel syndrome (IBS), as the result of an overactive nervous system.
Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.
Now a Mayo Clinic research team has identified a number of genetic variants in serotonin genes that impact irritable bowel syndrome or IBS.
NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc.
GOTHENBURG, Sweden, April 29, 2010 /PRNewswire/ -- Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation.
Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder that can greatly affect the patient's well being.
A Mayo Clinic research study published in the January issue of the American Journal of Gastroenterology finds that St. John's wort is not an effective treatment for irritable bowel syndrome (IBS).